BiotechTube

DS-6157a

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastrointestinal Stromal Tumors

Conditions

Gastrointestinal Stromal Tumors

Trial Timeline

May 8, 2020 → Mar 11, 2022

NCT ID
NCT04276415

About DS-6157a

DS-6157a is a phase 1 stage product being developed by Daiichi Sankyo for Gastrointestinal Stromal Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT04276415. Target conditions include Gastrointestinal Stromal Tumors.

What happened to similar drugs?

8 of 20 similar drugs in Gastrointestinal Stromal Tumors were approved

Approved (8) Terminated (3) Active (9)
✅Remimazolam TosilateJiangsu Hengrui MedicineApproved
✅Mycophenolate SodiumNovartisApproved
✅myforticNovartisApproved
✅Imatinib MesylateNovartisApproved
✅Imatinib mesylateNovartisApproved
✅NilotinibNovartisApproved
✅Sunitinib Malate (SU011248)PfizerApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04276415Phase 1Terminated

Competing Products

20 competing products in Gastrointestinal Stromal Tumors

See all competitors
ProductCompanyStageHype Score
Raludotatug Deruxtecan (R-DXd)Daiichi SankyoPhase 2
39
Patritumab deruxtecanDaiichi SankyoPhase 1/2
39
DS-8201a + Physician's ChoiceDaiichi SankyoPhase 2
35
Naldemedine + PlaceboShionogiPhase 2
27
GemcitabineEli LillyPhase 1/2
32
OlaratumabEli LillyPhase 2
27
pemetrexed + cisplatinEli LillyPhase 2
35
cetuximabEli LillyPhase 2
35
BBI503Sumitomo PharmaPhase 2
27
BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + RegorafenibSumitomo PharmaPhase 1/2
32
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
40
Placebo + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol)Johnson & JohnsonPhase 2
35
Remimazolam TosilateJiangsu Hengrui MedicineApproved
43
Famitinib capsules + Sunitinib CapsulesJiangsu Hengrui MedicinePhase 3
32
FamitinibJiangsu Hengrui MedicinePhase 2
31
Esomeprazole IV + Omeprazole IVAstraZenecaPhase 3
40
Durvalumab + FLOT chemotherapyAstraZenecaPhase 3
44
EsomeprazoleAstraZenecaPhase 3
40
AZD2171AstraZenecaPhase 2
35
EsomeprazoleAstraZenecaPhase 3
40